Loading
Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.
Graham Jackson was chief investigator of Myeloma XI, the largest myeloma trial ever run, which showed lenalidomide maintenance improves progression-free and overall survival in transplant-eligible patients and defined the benefit of triplet induction, and of the earlier Myeloma IX trial. He chairs the UK Myeloma Research Alliance and leads the RADAR trial of MRD-guided treatment.
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
Shares Newcastle Cancer Centre / Northern Centre for Cancer Care and the tag uk.
Shares Newcastle Cancer Centre / Northern Centre for Cancer Care and the tag uk.
Shares MRD / molecular residual disease testing and the tag uk.
Shares Multiple myeloma and the tag myeloma.
Shares Multiple myeloma and the tag myeloma.